Thu Sep 16 2021

suPAR measured using suPARnostic® TurbiLatex predicts critical illness and kidney failure in patients admitted to the intensive care unit


This study investigates the effectiveness and applicability of suPAR as a prognostic marker for patients in a medical ICU. It evaluates plasma levels of suPAR using an immunoturbidimetric test and incorporates them with the SOFA score risk stratification tool.

Methods and patients

We measured plasma suPAR levels in 237 consecutive, unselected patients admitted to the ICU using the suPARnostic® TurbiLatex kit. We then observed the outcomes, focusing on the mortality rate within 28 days of admission.


suPAR predicts kidney failure

  • Median suPAR levels were 8.0 ng/mL [25th-75th percentile 4.3–14.4], with lower levels in ICU survivors than non-survivors (6.7 vs. 11.6 ng/mL, p <0.001).
  • CRP levels were not associated with survival.
  • suPAR levels were higher in COVID-19, kidney disease, moderate-to-severe liver disease, and sepsis.
  • ICU mortality increased by an odds ratio (OR) of 4.7 in patients with the highest compared to the lowest quartile suPAR.
  • ICU mortality was:
    • 2% in patients with SOFA score ≤7 & suPAR ≤8 ng/ mL
    • 17% in patients with a SOFA score ≤7 and >8 ng/ mL


Our findings indicate that suPAR levels are linked to the risk of death in ICU patients, making it a highly valuable tool for identifying patients at moderate risk (with a SOFA score of 7 or lower). Additionally, suPAR proved to be a reliable indicator for predicting the occurrence of acute kidney injury.


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

Quick Triage

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research


Point-of-care finger prick

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates